MOU Signed with ACK to Build Digital Hospital Environments
Reducing Clinical Errors and Enhancing Convenience for Medical Staff
Daewoong Pharmaceutical announced on April 22 that it has signed a strategic memorandum of understanding (MOU) with Sears Technology and ACK for the widespread adoption of the smart bedside monitoring system 'ThynC™' across all hospital beds and for integration with hospital electronic medical records (EMR).
Joseonju ACK CEO (left in the photo), Changjae Lee CEO of Daewoong Pharmaceutical, and Youngshin Lee CEO of Sears Technology are signing a business agreement and taking a commemorative photo on the 21st at the Daewoong Pharmaceutical headquarters in Hwaseong, Gyeonggi. Daewoong Pharmaceutical
This agreement aims to enhance the convenience of patient management for medical staff by integrating ThynC, a next-generation digital healthcare solution, with hospital EMR systems. Furthermore, it seeks to promote the digital transformation of hospital operations.
Patient vital signs collected from the bedside monitoring system must be linked in real time with the hospital EMR system to ensure accurate record-keeping and to support prompt clinical decision-making. If integration is not achieved, there is a risk of data loss or increased workload for medical staff who would need to enter data manually, which could also lead to human error. Therefore, it is essential to secure stable and precise integration technology that can flexibly respond to the diverse IT environments of different hospitals.
Under this agreement, ACK will build and manage the interface that automatically links various medical data measured by ThynC with EMR systems. ACK is the leading healthcare IT solutions company in South Korea, having established EMR interfaces in more than 85% of tertiary hospitals nationwide. With over 25 years of experience in hospital system design and expertise, ACK provides stable and highly reliable integration services.
Through advanced technological collaboration with ACK, Sears Technology has established the foundation for building intelligent medical infrastructure for smart hospital innovation. This is achieved by processing various biometric signals collected from the ThynC wearable device?an essential component of the smart hospital ecosystem?on an artificial intelligence (AI)-based analysis platform and integrating them in real time with hospital EMR systems. The agreement is expected to not only improve the work efficiency of medical staff but also contribute to stable and systematic management of medical data.
Changjae Lee, CEO of Daewoong Pharmaceutical, stated, "This business agreement demonstrates Daewoong Pharmaceutical's strategic commitment to creating differentiated customer value and leading the market in the digital healthcare sector. Starting with ThynC, we will provide practical solutions that enhance the convenience of patient management for medical staff, from bedside monitoring to medical data integration, and accelerate innovation in the digital healthcare ecosystem through collaboration with partners who possess the best capabilities in each field."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
